- Mendelian Randomization to Evaluate the Causal Effect of Serum Bilirubin on Atrial Fibrillation
-
Hisamatsu T
- KMID: 2545133
- Korean Circ J.
- 2023 Jul;53(7):480-482.
- doi: 10.4070/kcj.2023.0075
-
- CITED
-
- Close
- SHARE
-
- Close
- Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
-
Yagisawa K, Kobayashi T, Ozaki R, Okabayashi S, Toyonaga T, Miura M, Hayashida M, Saito E, Nakano M, Matsubara H, Hisamatsu T, Hibi T
- KMID: 2504591
- Intest Res.
- 2020 Jul;18(3):343-344.
- doi: 10.5217/ir.2018.00078-c1
-
- CITED
-
- Close
- SHARE
-
- Close
- First aid with color atlas for the use of intestinal ultrasound for inflammatory bowel disease in daily clinical practice
-
Miyoshi J, Morikubo H, Yonezawa H, Mori H, Hisamatsu T
- KMID: 2541890
- Intest Res.
- 2023 Apr;21(2):177-188.
- doi: 10.5217/ir.2023.00003
Intestinal ultrasound (IUS) is a promising modality for the management of inflammatory bowel disease (IBD) and has the potential to particularly contribute in monitoring disease activity, an advantage crucial for... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
-
Hisamatsu T, Suzuki Y, Kobayashi M, Hagiwara T, Kawaberi T, Ogata H, Matsui T, Watanabe M, Hibi T
- KMID: 2521604
- Intest Res.
- 2021 Oct;19(4):408-418.
- doi: 10.5217/ir.2020.00025
Background/Aims: Crohn’s disease is a chronic disorder; therefore, it is essential to investigate long-term safety and efficacy of treatments. This study assessed the safety and effectiveness of adalimumab for up... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies
-
Kobayashi T, Matsuoka K, Watanabe M, Hisamatsu T, Hirai F, Milata J, Li X, Morris N, Arora V, Ishizuka T, Matsuo K, Satoi Y, Milch C, Hibi T
- KMID: 2554661
- Intest Res.
- 2024 Apr;22(2):172-185.
- doi: 10.5217/ir.2023.00043
Background/Aims: Mirikizumab is a p19-directed anti-interleukin-23 antibody with potential efficacy against ulcerative colitis (UC). We evaluated the efficacy and safety of mirikizumab in a Japanese subpopulation with moderately to severely... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
-
Hisamatsu T, Kim HJ, Motoya S, Suzuki Y, Ohnishi Y, Fujii N, Matsushima N, Zheng R, Marano CW
- KMID: 2521602
- Intest Res.
- 2021 Oct;19(4):386-397.
- doi: 10.5217/ir.2020.00080
Background/Aims: We aimed to evaluate the efficacy and safety of ustekinumab (UST) in the East-Asian population with moderate to severely active ulcerative colitis (UC). Methods: This sub-analysis was conducted on data... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
-
Song EM, Na SY, Hong SN, Ng SC, Hisamatsu T, Ye BD
- KMID: 2544757
- Intest Res.
- 2023 Jul;21(3):339-352.
- doi: 10.5217/ir.2022.00135
Background/Aims: As the characteristics of inflammatory bowel disease (IBD) differ between Asians and Westerners, it is necessary to determine adequate therapeutic strategy for Asian IBD patients. We evaluated the current... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
-
Hibi T, Motoya S, Hisamatsu T, Hirai F, Watanabe K, Matsuoka K, Saruta M, Kobayashi T, Feagan BG, Tasset C, Besuyen R, Yun C, Crans G, Zhang J, Kondo A, Watanabe M
- KMID: 2539010
- Intest Res.
- 2023 Jan;21(1):110-125.
- doi: 10.5217/ir.2021.00143
Background/Aims: The safety and efficacy of filgotinib, a once-daily oral Janus kinase 1 preferential inhibitor, were evaluated in Japanese patients with ulcerative colitis (UC) in the phase 2b/3 SELECTION trial. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
